Placebo News and Research

RSS

Epilepsy drug inhibits the growth of NF1 tumors in mice

People with neurofibromatosis type 1 (NF1) develop tumors on nerves throughout their bodies. These tumors are usually benign - meaning they don't spread to other parts of the body and are not considered life-threatening - but they can still cause serious medical problems such as blindness, especially when they form in the brain and nerves.

19 May 2022

Should children be vaccinated against COVID-19?

A new study conducted examines issues surrounding children between the ages of five and 11 who are eligible for vaccination against SARS-CoV-2.

18 May 2022

STOP-COVID19 trial: Brensocatib did not improve clinical status of patients with severe SARS-CoV-2 infection

Brensocatib did not improve the clinical status of patients hospitalized with severe SARS-CoV-2 infection in the double-blind randomized, placebo-controlled STOP-COVID19 multicenter clinical trial, according to research published at the ATS 2022 international conference.

18 May 2022

Treatment with imatinib results in lower mortality rates for patients with severe COVID-19

Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference.

18 May 2022

Consumption of cranberries could improve memory, ward off dementia, and lower 'bad' cholesterol

Adding cranberries to your diet could help improve memory and brain function, and lower ‘bad’ cholesterol – according to new research from the University of East Anglia (UK).

18 May 2022

Cannabidiol for Parkinson's disease symptom management

Scientists have published a review study in the Journal for Nurse Practitioners that has focussed on various aspects of the use of cannabidiol in Parkinson's.

17 May 2022

Multi-country study provides a clear treatment option for IgA nephropathy

The largest ever randomized controlled trial in IgA nephropathy has found that treatment with methylprednisolone - a cheap, widely used corticosteroid drug - halves the risk of losing kidney function and kidney failure, and that this can be effectively achieved with fewer side effects if a reduced dose is used.

17 May 2022

Study: Daily intake of Urolithin A improves muscle strength by 12% after four months

Age-associated muscle decline can start as early as 40 years old and there are currently no effective interventions to counteract it other than exercise.

17 May 2022

NAVIGATOR trial: Nearly half of asthma patients improved with tezepelumab treatment

A greater proportion of patients with severe, uncontrolled asthma had more significant clinical responses to tezepelumab than placebo, according to research published at the ATS 2022 international conference.

16 May 2022

Immunotherapy after bladder cancer surgery helps reduce cancer recurrence

Immunotherapy after surgery helped reduce cancer recurrence in patients with urothelial cancer of the bladder or other sites in the urinary tract that had invaded the muscle and therefore posed a high risk for recurrence, according to clinical trial results presented at the American Urological Association annual meeting in May.

15 May 2022

The safety, immunogenicity, and efficacy of the mRNA-1273 vaccine in children aged 6-11

In a recent study published in The New England Journal of Medicine, researchers evaluated the safety, immunogenicity, and efficacy of the messenger ribonucleic acid (mRNA)-1273 vaccine in children.

13 May 2022

Phase 1 trial of COVID-19 PTXCOVID19-B vaccine

A new study demonstrated that the SARS-CoV-2 PTXCOVID19-B vaccine was a promising SARS-CoV-2 vaccine option.

12 May 2022

Daily blueberry intake may lower the chances of developing late-life dementia

The old adage says that an apple a day keeps the doctor away, but new research from the University of Cincinnati shows the potential benefit of a different fruit for your health.

11 May 2022

First oral antiviral approved for early treatment of COVID-19

The United States Food and Drug Administration granted an Emergency Use Authorization in December 2021 for the first oral antiviral, a pill containing two protease inhibitors – nirmatrelvir and ritonavir (Paxlovid, Pfizer) – for early treatment of COVID-19.

11 May 2022

Remdesivir shows no significant effect on patients with COVID-19 in Solidarity trial

A recent study published in the journal The Lancet summarized the final results of the Solidarity trial which aimed at finding out which drugs were most effective at reducing the severity of the disease among hospitalized patients.

9 May 2022

ZF2001 vaccine safe and effective against symptomatic and severe-to-critical COVID

A new study published in the New England Journal of Medicine has discussed the efficacy and safety profile of the ZF2001 vaccine in adults, based on a randomized, placebo-controlled, multinational, double-blind phase 3 trial.

9 May 2022

Evaluating the findings of phase 3 clinical trial of plant-based COVID-19 vaccine

A new study has presented the safety and efficacy profiles of a plant-based adjuvanted coronavirus disease 2019 (COVID-19) vaccine in human participants.

5 May 2022

Dopamine plays a significant role in recognizing human emotions, new study reveals

The neurotransmitter dopamine, famous for its role in reward, is also involved in recognizing emotions, according to new research published in JNeurosci.

3 May 2022

Trial shows the efficacy of anti-TNF drug for patients with early-stage Dupuytren's disease

Researchers at the Kennedy Institute, University of Oxford, led by Professor Jagdeep Nanchahal have demonstrated the efficacy of the anti-TNF drug adalimumab for patients with early-stage Dupuytren's disease.

30 Apr 2022

Dapagliflozin did not reduce risks in patients hospitalized with COVID-19

In a recent randomized clinical trial of hospitalized patients with COVID-19 and cardio-metabolic risk factors, the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin did not significantly reduce patients' risk of organ failure, kidney problems, or death compared with placebo, although numerically fewer participants treated with dapagliflozin experienced these outcomes. The findings are published in CJASN.

29 Apr 2022

Placebo News and Research

Epilepsy drug inhibits the growth of NF1 tumors in mice

Should children be vaccinated against COVID-19?

STOP-COVID19 trial: Brensocatib did not improve clinical status of patients with severe SARS-CoV-2 infection

Treatment with imatinib results in lower mortality rates for patients with severe COVID-19

Consumption of cranberries could improve memory, ward off dementia, and lower 'bad' cholesterol

Cannabidiol for Parkinson's disease symptom management

Multi-country study provides a clear treatment option for IgA nephropathy

Study: Daily intake of Urolithin A improves muscle strength by 12% after four months

NAVIGATOR trial: Nearly half of asthma patients improved with tezepelumab treatment

Immunotherapy after bladder cancer surgery helps reduce cancer recurrence

The safety, immunogenicity, and efficacy of the mRNA-1273 vaccine in children aged 6-11

Phase 1 trial of COVID-19 PTXCOVID19-B vaccine

Daily blueberry intake may lower the chances of developing late-life dementia

First oral antiviral approved for early treatment of COVID-19

Remdesivir shows no significant effect on patients with COVID-19 in Solidarity trial

ZF2001 vaccine safe and effective against symptomatic and severe-to-critical COVID

Evaluating the findings of phase 3 clinical trial of plant-based COVID-19 vaccine

Dopamine plays a significant role in recognizing human emotions, new study reveals

Trial shows the efficacy of anti-TNF drug for patients with early-stage Dupuytren's disease

Dapagliflozin did not reduce risks in patients hospitalized with COVID-19

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News